Pharmaceutical Contract Manufacturing (PCM) – Forecast to 2030 is estimated to be worth $100,102.8 million by 2030


IQ4I Research & Consultancy published a new report on “Pharmaceutical Contract Manufacturing (PCM) Global Market – Forecast To 2030” 

This Pharmaceutical Contract Manufacturing global market report covers four segments namely Product, Application, and Geography. These segments are further segmented as follows:

Pharmaceutical Contract Manufacturing (PCM) Global Market, Based on Product:

  • API Manufacturing
    • Branded API Manufacturing
    • Generic API Manufacturing
  •  Finished dosage form (FDF) Manufacturing
    • Solid Dosage Forms
  • Tablets
  • Capsules
  • Others (Powders and Granules)
    • Injectables Dosage Forms
    • Semisolid, Liquid and Gaseous Dosage Forms


 Pharmaceutical Contract Manufacturing (PCM) Global Market, Based on Phase

  • Clinical Manufacturing
  • Commercial Manufacturing


 Pharmaceutical Contract Manufacturing (PCM) Global Market, Based on Application

  • Oncology
  • Central Nervous System
  • Cardiovascular Diseases
  • Infectious Diseases
  • Pulmonary Diseases
  • Metabolic Diseases
  • Gastrointestinal Diseases
  • Musculoskeletal Diseases
  • Genitourinary Diseases
  • Endocrine Diseases
  • Other Applications


Pharmaceutical Contract Manufacturing (PCM) Global Market, Based on Geography:

  • North America (U.S. and Rest of NA)
  • Europe (Germany, France, Italy, and Rest of Europe)
  • Asia-Pacific (China, India, Japan, and Rest of APAC)
  • Rest of World (Brazil, Rest of Latin America and Middle East and Others)


Each segment of this report offers market values for its sub-segments and geographies as well. It also provides market dynamics with respect to drivers, restraints, opportunities, and the performance of major key players.

According to IQ4I analysis, the pharmaceutical contract manufacturing (PCM) global market is expected to grow at a mid single digit CAGR from 2023 to 2030 to reach $100,102.8 million by 2030. The market is being propelled by several factors, including the increased trend of outsourcing and high uptake of small molecules drugs across diverse therapeutics are driving the pharmaceutical contract manufacturing global market. Whereas, patent expiration and increasing adoption of 505(b)(2) pathway of small molecules drugs, advanced technologies in API and FDF manufacturing, increasing R&D expenditures and Capacity and Capability Expansion in advanced Highly Potent APIs and Complex Molecules platforms are providing immense opportunities to the market. However, contamination of pharmaceutical products (API and FDF), pricing pressure for pharmaceutical contract manufacturing, requirement of highly skilled technicians, increasing biologics approvals and adoption in disease management, stringent regulatory policies, and environmental concerns are some of the factors that are hindering pharmaceutical contract manufacturing global market growth.


The report covers business intelligence information of the pharmaceutical contract manufacturing global market segments based on product, application, and geography. Revenue forecast and strategic analysis with respect to industry trends and contribution to the overall pharmaceutical contract manufacturing global market. Analysis technological trends, overall market share, market share analysis of major players, deals analysis, production volume analysis, ANDA approvals, patent analysis, DMF analysis, supply chain of and PCM product matrix. Identification of major market trends, factors driving, restraining, threatening and providing opportunities for the pharmaceutical contract manufacturing market growth. Major players’ company profiles in the pharmaceutical contract manufacturing Global market and analysis of their business strategies and market shares.


The major companies in pharmaceutical contract manufacturing are AbbVie Inc (AbbVie Contract Manufacturing) (U.S.), Asymchem Laboratories (Tianjin) (China), Cambrex Corporation (U.S.), Curia (U.S.), Delpharm (France), Lonza Group (Switzerland), Porton Pharma Solutions Ltd (China), Recipharm (Sweden), Thermo Fisher Scientific (U.S.) and WuXi AppTec (China).